Diabetic foot ulcers cause more than 80,000 lower-limb amputations per year in the United States, and the lifetime amputation risk for a DFU patient is roughly 20%. See the diabetic foot ulcer evidence atlas for the full study-by-study evidence breakdown.
HBOT has been used as an adjunct DFU treatment for more than three decades. The clinical evidence is among the strongest of any HBOT indication — strong enough that CMS, the UHMS, and the Wound Healing Society all recognize it as standard of care for advanced DFUs that have failed first-line management.
This guide walks through what the highest-quality trial evidence says, who benefits most, and how to evaluate whether HBOT belongs in your DFU treatment plan.
What the Cochrane Evidence Shows
The most-cited systematic review of HBOT for chronic wounds is the Cochrane HBOT for Chronic Wounds review (2024).
The 2024 update analyzed multiple randomized controlled trials covering diabetic foot ulcers as well as other chronic wound types. For DFUs specifically, the review found HBOT reduced the risk of major amputation compared to standard care alone — the clinical endpoint that matters most for these patients.
Healing rates also favored HBOT. Time-to-complete-healing was shorter in HBOT-treated cohorts across multiple included trials.
The Cochrane reviewers noted heterogeneity in protocol design and emphasized that patient selection matters — HBOT works best for ischemic and inflammatory DFUs that have not responded to 30 days of optimal standard wound care.
The Major Randomized Controlled Trials
Three randomized controlled trials anchor the contemporary HBOT-for-DFU evidence base.
Faglia 1996
The Faglia et al. 1996 trial — published in Diabetes Care — randomized 70 patients with severe diabetic foot lesions to HBOT plus standard care or standard care alone. Major amputation occurred in 8.6% of the HBOT group versus 33.3% of controls.
This trial established HBOT's place in the DFU treatment algorithm.
Abidia 2003
The Abidia et al. 2003 trial — published in the European Journal of Vascular and Endovascular Surgery — randomized 18 patients with non-healing DFUs to HBOT or sham. At 1-year follow-up, 5 of 8 HBOT-treated ulcers had completely healed compared to 1 of 8 sham-treated ulcers.
Löndahl 2010 (HODFU)
The Löndahl et al. 2010 HODFU trial — published in Diabetes Care — was the largest sham-controlled trial. It randomized 94 patients with Wagner grade 2-4 DFUs that had been present for at least 3 months.
HBOT-treated patients showed significantly improved complete healing at 1 year (61% vs 27%, p=0.009).
These three trials, combined with subsequent observational data, drive the current CMS and UHMS recommendations.
What CMS Actually Covers
The CMS National Coverage Determination 20.29 (active 2026) sets specific criteria for HBOT coverage in DFU.
Medicare covers HBOT for diabetic wounds of the lower extremity when ALL of the following are met:
- The patient has Type 1 or Type 2 diabetes with a lower extremity wound
- The wound is classified Wagner grade 3 or higher
- The patient has failed an adequate course of standard wound therapy (at least 30 days of optimized care)
- HBOT is used in addition to — not in place of — standard wound care
If after 30 days of HBOT no measurable signs of healing are documented, Medicare will not pay for additional sessions.
This is the framework most commercial insurers also follow for DFU coverage.
The UHMS Recommended Protocol
The UHMS HBO Indications 13th Edition (2024) describes the standard DFU protocol in detail.
Pressure: 2.0-2.5 ATA
Session length: 90 minutes of treatment time at pressure, plus 5-15 minutes of pressurization and depressurization
Frequency: 5 sessions per week (Monday-Friday)
Total sessions: 20-40, depending on response
Setting: UHMS-accredited facility under physician supervision, typically a hospital-based hyperbaric medicine program
The Wound Healing Society's clinical practice guidelines align with the UHMS protocol and explicitly recommend HBOT for Wagner grade 3+ DFUs that have failed standard care.
Who Benefits Most From HBOT
The strongest evidence is for patients with:
- Wagner grade 3-4 ulcers with exposed bone, tendon, or joint involvement
- Ischemic component confirmed by transcutaneous oxygen measurement (TcPO2) demonstrating tissue hypoxia at baseline that increases under HBOT challenge
- No major arterial occlusion requiring revascularization first — HBOT is not a substitute for restoring perfusion
- Adequate offloading of the wound site
- Adequate infection control including appropriate debridement and antibiotics
- Diabetes management with HbA1c trending toward goal
The IWGDF Diabetic Foot Guidelines (2023) emphasize this multi-modal approach. HBOT alone, without the other elements, is unlikely to heal a complex DFU.
Who Benefits Less
Patients with:
- Wagner grade 1-2 ulcers that are likely to heal with standard care alone
- Major arterial occlusion that has not been revascularized — HBOT cannot perfuse tissue with no blood supply
- Uncontrolled infection requiring surgical management before any wound-healing adjuncts
- End-stage renal disease on hemodialysis — small studies suggest reduced HBOT effectiveness in this population
How HBOT Heals Diabetic Wounds
The mechanism is multi-modal and reasonably well-characterized.
Increased tissue oxygenation: per Henry's Law, dissolved plasma oxygen rises roughly 15-fold at 2.0 ATA breathing pure oxygen. This dissolved oxygen perfuses tissues that have compromised microcirculation.
Angiogenesis: HBOT activates hypoxia-inducible factor 1-alpha during reperfusion, increasing VEGF production and driving new capillary network formation over 20-40 sessions.
Stem cell mobilization: a Thom et al. 2006 study in the American Journal of Physiology found single HBOT sessions doubled circulating CD34+ stem cells, with 20 sessions increasing counts up to 8-fold. These cells migrate to wound tissue.
Anti-microbial effect: pressurized oxygen is directly toxic to anaerobic bacteria and enhances neutrophil oxidative burst killing of facultative anaerobes commonly found in diabetic foot infections.
Reduced edema: HBOT causes mild vasoconstriction that reduces tissue edema without compromising oxygenation.
Collagen synthesis: hyperoxia is required for hydroxylation of proline and lysine residues during collagen synthesis — critical for wound matrix formation.
These mechanisms are described in detail in the UHMS 13th Edition Indications (2024) DFU chapter.
Cost and Insurance
A standard 30-session DFU protocol at a UHMS-accredited hospital typically bills $30,000-$60,000 before insurance.
Medicare Part B covers HBOT for qualifying DFU at 80% of the approved amount, after the annual deductible. Commercial insurance generally follows Medicare for medical-necessity determinations, with prior authorization required.
Out-of-pocket cost after insurance varies widely. Patients with Medicare and a Medigap policy may pay little to nothing. Patients with high-deductible commercial plans may face significant cost-sharing.
The cost-effectiveness math is favorable when measured against amputation alternatives. Lower-extremity amputations average roughly $70,000 in initial surgical and rehabilitation costs, with additional lifetime costs for prosthetics, mobility aids, and reduced quality-adjusted life-years.
The Cochrane review (2024) noted that HBOT is cost-effective when limb-salvage is a realistic clinical outcome.
Safety Considerations Specific to DFU Patients
The general HBOT safety profile is favorable, but DFU patients often have comorbidities that warrant specific attention.
Hypoglycemia risk: HBOT can lower blood glucose. Patients on insulin or sulfonylureas should test before and after each session, eat a light meal beforehand, and have rescue glucose available.
Cardiovascular comorbidity: many DFU patients also have heart failure or coronary artery disease. Pre-treatment evaluation should include cardiac risk assessment per the UHMS Accreditation Manual (2023).
Eye effects: progressive nuclear cataract can accelerate with long HBOT protocols. Patients with pre-existing cataracts should be informed.
Pulmonary considerations: COPD with bullous disease is a relative contraindication. Pulmonary function testing should be considered for at-risk patients.
The only absolute contraindication remains untreated pneumothorax per StatPearls HBOT Contraindications (2024).
Active Clinical Trials
Several DFU-specific HBOT trials are ongoing or recently completed, registered on ClinicalTrials.gov.
These include trials investigating:
- Optimal session number for ischemic vs neuropathic DFU subtypes
- Combination protocols pairing HBOT with negative pressure wound therapy
- TcPO2-guided patient selection algorithms
- Cost-effectiveness comparisons against newer wound-care biologics
Results from these trials may further refine the DFU protocol and patient-selection criteria in the next 2-3 years.
Frequently Asked Questions
Is HBOT a substitute for diabetic foot ulcer surgery or revascularization?
No. HBOT is an adjunct to — not a substitute for — proper wound debridement, infection control, offloading, and vascular assessment. Patients with major arterial occlusion typically need revascularization first because HBOT cannot oxygenate tissue with no blood supply. The IWGDF Guidelines (2023) emphasize the multi-modal approach. HBOT should be considered after 30 days of optimized standard wound care has failed, per the CMS NCD 20.29 (active 2026) criteria.
How long until HBOT shows results for a diabetic foot ulcer?
Most patients show measurable healing within 20-30 sessions, which corresponds to roughly 4-6 weeks of 5-day-per-week treatment. The Löndahl 2010 HODFU trial measured complete healing at 1-year follow-up, with HBOT-treated patients achieving 61% complete healing versus 27% of sham controls. Medicare requires documented signs of healing within the first 30 days of HBOT to continue coverage.
Does mild HBOT at 1.3 ATA work for diabetic foot ulcers?
No. The clinical evidence and FDA clearance specifically apply to 2.0-2.5 ATA protocols at UHMS-accredited facilities. Mild HBOT at 1.3 ATA produces far less plasma oxygen elevation per Henry's Law, and no quality randomized controlled trials have shown DFU benefit at these lower pressures. The FDA Safety Communication (2021, reaffirmed 2024) warns that mild HBOT may not produce the same physiologic effects.
Will Medicare cover HBOT for my diabetic foot ulcer in 2026?
Medicare covers HBOT for DFU when the wound is Wagner grade 3 or higher, the patient has failed 30 days of standard wound care, and HBOT is used as adjunct to ongoing wound care, per CMS NCD 20.29 (active 2026). Medicare Part B reimburses 80% of the approved amount after the annual deductible. If no measurable healing is documented in the first 30 days of HBOT, Medicare will not pay for additional sessions.
What's the difference between hospital HBOT and wound-care-center HBOT?
Both can deliver UHMS-protocol HBOT for DFU if they are UHMS-accredited and operate hard-shell chambers at 2.0-2.5 ATA under physician supervision. Hospital-based programs typically integrate HBOT into a comprehensive wound-care service with vascular surgery, infectious disease, and endocrinology consultation available. Free-standing wound care centers may also be excellent but should be evaluated on UHMS accreditation status, physician oversight, and pre-treatment vascular and infection assessment per the UHMS Accreditation Manual (2023).
Find HBOT Centers Treating Diabetic Foot Ulcers
Browse our complete directory of UHMS-accredited HBOT centers to find verified facilities that treat diabetic foot ulcers under physician supervision.
-- The HBOT Finder Team
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Diabetic foot ulcer is a serious condition requiring multi-disciplinary care. The information here describes the evidence base for HBOT as an adjunctive therapy per CMS NCD 20.29 (active 2026) and the UHMS 13th Edition Indications (2024). Always consult your wound care physician and follow the IWGDF Guidelines (2023) recommended care pathway.
Editorial Disclosure: HBOT Finder maintains editorial independence. We do not accept paid placements in our directory.